PL2523666T3 - Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-5-alfa-pregnan-20-on o ulepszonych właściwościach przechowywania i rozpuszczalności - Google Patents
Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-5-alfa-pregnan-20-on o ulepszonych właściwościach przechowywania i rozpuszczalnościInfo
- Publication number
- PL2523666T3 PL2523666T3 PL11733156T PL11733156T PL2523666T3 PL 2523666 T3 PL2523666 T3 PL 2523666T3 PL 11733156 T PL11733156 T PL 11733156T PL 11733156 T PL11733156 T PL 11733156T PL 2523666 T3 PL2523666 T3 PL 2523666T3
- Authority
- PL
- Poland
- Prior art keywords
- pregnan
- beta
- alpha
- hydroxy
- pharmaceutical composition
- Prior art date
Links
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29502710P | 2010-01-14 | 2010-01-14 | |
| SE1050029 | 2010-01-14 | ||
| EP11733156.1A EP2523666B8 (en) | 2010-01-14 | 2011-01-14 | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| PCT/SE2011/050036 WO2011087441A1 (en) | 2010-01-14 | 2011-01-14 | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2523666T3 true PL2523666T3 (pl) | 2016-06-30 |
Family
ID=44304503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11733156T PL2523666T3 (pl) | 2010-01-14 | 2011-01-14 | Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-5-alfa-pregnan-20-on o ulepszonych właściwościach przechowywania i rozpuszczalności |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20120322781A1 (pl) |
| EP (1) | EP2523666B8 (pl) |
| JP (1) | JP5687287B2 (pl) |
| CN (1) | CN102753181B (pl) |
| AU (1) | AU2011205821B2 (pl) |
| BR (1) | BR112012017136B1 (pl) |
| CA (1) | CA2786330C (pl) |
| DK (1) | DK2523666T3 (pl) |
| ES (1) | ES2566765T3 (pl) |
| HU (1) | HUE027298T2 (pl) |
| MX (1) | MX2012008257A (pl) |
| PL (1) | PL2523666T3 (pl) |
| RU (1) | RU2012133627A (pl) |
| WO (1) | WO2011087441A1 (pl) |
| ZA (1) | ZA201204574B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013043985A1 (en) * | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN106146597A (zh) * | 2016-07-05 | 2016-11-23 | 浙江海洋大学 | 一种马尾藻甾醇化合物及其提取方法、应用 |
| CN106146596A (zh) * | 2016-07-05 | 2016-11-23 | 浙江海洋大学 | 一种铜藻β‑谷甾醇化合物及其提取方法、应用 |
| KR102185474B1 (ko) * | 2016-09-27 | 2020-12-03 | 광시 지우푸 바이오테크놀로지 컴퍼니 리미티드 | 마약중독 치료효과가 있는 추출물 및 그 제조방법 |
| MX393759B (es) | 2017-01-09 | 2025-03-24 | Asarina Pharma Ab | Suspensiones inyectables |
| WO2018147792A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |
| CN111432805B (zh) | 2017-11-27 | 2023-02-17 | 梅克里内科尼蒂翁公司 | 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂 |
| WO2020011789A1 (en) | 2018-07-09 | 2020-01-16 | Asarina Pharma Ab | Injectable suspensions |
| EP3593789A1 (fr) * | 2018-07-11 | 2020-01-15 | Beta Innov | Composition contenant un dérivé de 7beta-hydroxycholestérol et un véhicule lipidique, et son utilisation dans le traitement de pathologies néoplasiques |
| US20220202832A1 (en) * | 2019-04-05 | 2022-06-30 | The Regents Of The University Of California | Allopregnanolone compositions and uses thereof |
| CN112341511A (zh) * | 2019-08-09 | 2021-02-09 | 南京诺瑞特医药科技有限公司 | 3-羟基-5-孕烷-20-酮衍生物及其用途 |
| CN114907436A (zh) * | 2021-02-08 | 2022-08-16 | 南京诺瑞特医药科技有限公司 | 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途 |
| US20240180865A1 (en) * | 2021-04-08 | 2024-06-06 | Tionlab Therapeutics | Sustained-release lipid pre-concentrate |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54122719A (en) * | 1978-03-16 | 1979-09-22 | Sankyo Co Ltd | Carcinostatic agent for oral administration |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| JPH02286625A (ja) * | 1989-04-27 | 1990-11-26 | Dainippon Pharmaceut Co Ltd | 注射用持続性製剤 |
| FR2663224B1 (fr) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| US5449474A (en) | 1992-02-21 | 1995-09-12 | Inland Technology, Inc. | Low toxicity solvent composition |
| SE9302295D0 (sv) | 1993-07-02 | 1993-07-02 | Kabi Pharmacia Ab | New pharmaceutical composition |
| AU7569194A (en) | 1993-08-20 | 1995-03-21 | Meyer B. Jackson | Method for regulating neuropeptide hormone secretion |
| US5763431A (en) | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| CN1171114A (zh) | 1994-11-23 | 1998-01-21 | 科斯赛斯公司 | 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系 |
| FR2734418A1 (fr) * | 1995-05-16 | 1996-11-22 | Amp France | Connecteur, notamment du type jack modulaire |
| CA2289006A1 (en) * | 1997-05-02 | 1998-11-12 | American Home Products Corporation | Pregnan-3-ol-20-ones |
| CN1270718C (zh) * | 1998-03-11 | 2006-08-23 | 托布乔恩·贝克斯托罗姆 | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 |
| US6075058A (en) | 1998-12-12 | 2000-06-13 | Tufts University | Compositions for increased bioavailability of carotenoids |
| WO2000059945A1 (en) | 1999-04-06 | 2000-10-12 | The Horticulture And Food Research Institute Of New Zealand Limited | Improvements in or relating to immunoassays for anaesthetics |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| AU6381000A (en) | 1999-07-29 | 2001-02-19 | Interneuron Pharmaceuticals, Inc. | Methods and compositions for alleviating stuttering |
| US20040204490A1 (en) | 1999-08-31 | 2004-10-14 | Farb David H. | Effect of steroids on NMDA receptors depends on subunit composition |
| DE60041773D1 (de) | 1999-08-31 | 2009-04-23 | Univ Boston | Der effekt von steroiden auf ndma-rezeptoren beruht auf der zusammensetzung der untereinheiten |
| US6855721B1 (en) * | 2000-07-28 | 2005-02-15 | Indevus Pharmaceuticals, Inc. | Methods and compositions for alleviating stuttering |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| US6888721B1 (en) | 2002-10-18 | 2005-05-03 | Atec Corporation | Electrohydrodynamic (EHD) thin film evaporator with splayed electrodes |
| US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| ES2423493T3 (es) | 2004-11-18 | 2013-09-20 | Umecrine Ab | Antagonistas de los GABA-esteroides y su uso para el tratamiento de trastornos del SNC |
| IN2014DN02014A (pl) | 2006-11-21 | 2015-07-10 | Umecrine Ab |
-
2011
- 2011-01-14 CA CA2786330A patent/CA2786330C/en active Active
- 2011-01-14 CN CN201180005620.9A patent/CN102753181B/zh active Active
- 2011-01-14 MX MX2012008257A patent/MX2012008257A/es active IP Right Grant
- 2011-01-14 RU RU2012133627/15A patent/RU2012133627A/ru not_active Application Discontinuation
- 2011-01-14 US US13/522,081 patent/US20120322781A1/en not_active Abandoned
- 2011-01-14 AU AU2011205821A patent/AU2011205821B2/en active Active
- 2011-01-14 HU HUE11733156A patent/HUE027298T2/en unknown
- 2011-01-14 EP EP11733156.1A patent/EP2523666B8/en active Active
- 2011-01-14 PL PL11733156T patent/PL2523666T3/pl unknown
- 2011-01-14 BR BR112012017136-4A patent/BR112012017136B1/pt active IP Right Grant
- 2011-01-14 WO PCT/SE2011/050036 patent/WO2011087441A1/en not_active Ceased
- 2011-01-14 ES ES11733156.1T patent/ES2566765T3/es active Active
- 2011-01-14 JP JP2012548918A patent/JP5687287B2/ja active Active
- 2011-01-14 DK DK11733156.1T patent/DK2523666T3/en active
-
2012
- 2012-06-20 ZA ZA2012/04574A patent/ZA201204574B/en unknown
-
2015
- 2015-02-19 US US14/626,490 patent/US9687496B2/en active Active
-
2017
- 2017-05-22 US US15/601,214 patent/US11534446B2/en active Active
-
2022
- 2022-11-17 US US18/056,475 patent/US20230117905A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012017136A2 (pt) | 2018-06-12 |
| CN102753181B (zh) | 2014-09-17 |
| US20120322781A1 (en) | 2012-12-20 |
| US20230117905A1 (en) | 2023-04-20 |
| JP5687287B2 (ja) | 2015-03-18 |
| BR112012017136B1 (pt) | 2021-05-25 |
| CA2786330A1 (en) | 2011-07-21 |
| AU2011205821A1 (en) | 2012-07-12 |
| HUE027298T2 (en) | 2016-10-28 |
| US9687496B2 (en) | 2017-06-27 |
| ZA201204574B (en) | 2013-08-28 |
| RU2012133627A (ru) | 2014-04-20 |
| CN102753181A (zh) | 2012-10-24 |
| JP2013517269A (ja) | 2013-05-16 |
| US20170258809A1 (en) | 2017-09-14 |
| ES2566765T3 (es) | 2016-04-15 |
| EP2523666B1 (en) | 2016-01-13 |
| US11534446B2 (en) | 2022-12-27 |
| EP2523666A4 (en) | 2013-07-03 |
| DK2523666T3 (en) | 2016-04-04 |
| AU2011205821B2 (en) | 2013-07-25 |
| WO2011087441A1 (en) | 2011-07-21 |
| EP2523666A1 (en) | 2012-11-21 |
| MX2012008257A (es) | 2012-11-21 |
| EP2523666B8 (en) | 2016-04-06 |
| CA2786330C (en) | 2013-11-19 |
| US20150164914A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2523666T3 (pl) | Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-5-alfa-pregnan-20-on o ulepszonych właściwościach przechowywania i rozpuszczalności | |
| IL257517B (en) | Integrin agonist compounds and medicinal compositions thereof | |
| IL253870B (en) | Certain amino-pyrimidines and pharmaceutical preparations containing them | |
| EP2570361A4 (en) | ARTICLE STORAGE BOX | |
| IL247079A0 (en) | A rapidly dissolving pharmaceutical compound | |
| IL215825A0 (en) | Selable storage container | |
| EP2642983A4 (en) | DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT | |
| PL2411025T3 (pl) | Stabilna w wysokiej temperaturze kompozycja farmaceutyczna zawierająca nośnik tlenu | |
| TWM388065U (en) | Rotary and telescopic storage device | |
| ZA201302120B (en) | Biodegradable drug delivery composition | |
| IL222086A (en) | A pharmaceutical composition that melts quickly | |
| EP2636666A4 (en) | TRANS-2 DECENTRIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF | |
| IL239297A0 (en) | Tablets with improved reception and good storage stability | |
| IL206739A0 (en) | Injectable pharmaceutical composition | |
| GB201019296D0 (en) | Storing and retrieving garments | |
| IL223707A0 (en) | N-hydroxyformamide derivative and medicament containing same | |
| ZA201208210B (en) | A combination composition comprising ibuprofen and paracetamal | |
| IL221501A (en) | Medicinal product containing miramistine | |
| ZA201205684B (en) | Ester compound and use thereof | |
| AP2788A (en) | Simalikalactone E and use thereof as a medicament | |
| SI2415681T1 (sl) | Skladiščna in transportna priprava | |
| ZA201300098B (en) | Pharmaceutical composition with enhanced solubility characteristics | |
| PL2857014T3 (pl) | Kompozycja farmaceutyczna zawierająca aspirynę i bisoprolol | |
| GB201001026D0 (en) | Article for storage and play | |
| TWM401636U (en) | Display box with storage and display effects |